Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169327 | 0.83 | NR1H3 (0.53) | HSD17B1HSD17B2F2NR1H3L3MBTL1 | |
| SCHEMBL10211749 | 0.82 | ALDH1A1 (0.52) | CYP11B1CYP11B2HSD17B1HSD17B2F2 | |
| SCHEMBL9959448 | 0.80 | CA12 (0.56) | CYP11B1CYP11B2NAPRTNR1H3L3MBTL1 | |
| SCHEMBL10169507 | 0.78 | HSD17B1 (0.48) | HSD17B1HSD17B2NR1H3L3MBTL1 | |
| SCHEMBL18085884 | 0.77 | LMNA (0.55) | HSD17B1HSD17B2L3MBTL1 | |
| SCHEMBL10169508 | 0.77 | FFAR1 (0.50) | HSD17B1HSD17B2NR1H3L3MBTL1 | |
| SCHEMBL10169504 | 0.76 | HSD17B1 (0.59) | HSD17B1HSD17B2NR1H3L3MBTL1 | |
| SCHEMBL10169506 | 0.76 | NPC1 (0.60) | HSD17B1HSD17B2L3MBTL1 | |
| SCHEMBL10169213 | 0.74 | ALDH1A1 (0.48) | L3MBTL1 | |
| SCHEMBL5609778 | 0.73 | CYP11B1 (0.49) | CYP11B1CYP11B2HSD17B1HSD17B2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | CYP11B1 1363/4885CYP11B2 1625/4885GRM2 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.